Blau Farmacêutica S.A. completed the acquisition of Laboratorio Quimico Farmaceutico Bergamo Ltda from Amgen Inc. for $33.2 million.
June 29, 2023
Share
Blau Farmacêutica S.A. (BOVESPA:BLAU3) agreed to acquire Laboratorio Quimico Farmaceutico Bergamo Ltda from Amgen Inc. (NasdaqGS:AMGN) for $28 million on October 31, 2022. As on May 4, 2023, Brazilian antitrust authority approved the transaction without restrictions. The closing is subject to compliance with certain precedent conditions.
Blau Farmacêutica S.A. (BOVESPA:BLAU3) completed the acquisition of Laboratorio Quimico Farmaceutico Bergamo Ltda from Amgen Inc. (NasdaqGS:AMGN) for $33.2 million on June 30, 2023. The payment consisted of an acquisition price of $28 million, an additional $4.7 million in excess cash, and $0.5 million for contractual adjustments. The transaction was finalised on June 30, with $27.6 million paid upfront and the remaining $5.6 million to be paid within 90 days. Laboratório Bergamo achieved net revenues of $35.57 million for 2022(unaudited).
Blau Farmaceutica SA is a Brazil-based company engaged in the pharmaceuticals sector. The Company focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The Company operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.
BLAU FARMACÊUTICA S.A. 
